Capricor Therapeutics Investors Face September 28 Lead Plaintiff Deadline

The litigation centers on allegations that Capricor Therapeutics misled shareholders regarding the regulatory pathway for its drug candidate, Deramiocel. The suit claims the company failed to disclose that it had altered its pre-specified statistical analysis plan for clinical data without prior FDA agreement. Consequently, plaintiffs argue that the firm knowingly obscured the elevated risk that regulators would reject the drug’s effectiveness for treating Duchenne muscular dystrophy.

By allegedly omitting these critical regulatory hurdles, the company’s public statements concerning its business prospects were purportedly devoid of a reasonable basis. Shareholders who purchased stock during the specified period and suffered financial harm are invited to contact Howard G. Smith at 215-638-4847 or via the firm's website to review their legal options. Participation in the class action does not require immediate individual action from those who choose to remain absent members of the suit.